Astrana Health, Inc. (ASTH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue and EBITDA growth projections, a positive impact from Medicare Advantage rate adjustments, and successful AI integration. The Q&A session reinforces these positives with details on AI benefits and strategic advantages. Despite some uncertainties, the overall sentiment is optimistic, suggesting a positive stock price movement.
Key Financial Performance
Revenue $965.1 million, up 56% year-over-year, driven by the full quarter contribution from Prospect, commencement of full risk contracts, and continued organic growth across the Care Partners segment.
Adjusted EBITDA $66.3 million, up 82% year-over-year, reflecting the durability of the model and disciplined platform-wide performance.
Non-GAAP Adjusted EPS $0.74, up 76% year-over-year, reflecting strong operating performance.
Free Cash Flow $64.1 million, reflecting strong operating performance, conversions to full risk, and disciplined platform-wide performance.
Net Leverage Approximately 2.3x on a pro forma trailing 12-month basis, down from 2.6x at year-end, reflecting strong free cash flow generation and continued EBITDA growth.
G&A as a Percentage of Revenue 6.4%, a 70 basis point improvement year-over-year, reflecting continued operating leverage and embedding of AI capabilities across the enterprise.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-enabled platform: Astrana has built an AI-enabled platform integrated with a longitudinal payer-agnostic care model, which is increasingly advantageous in the healthcare environment. AI agents are embedded into operational and clinical workflows, improving tasks like claims processing, care management, and patient engagement.
New full-risk contracts: Astrana commenced new full-risk contracts in Q1 2026, which are performing in line with underwriting expectations. Approximately 80% of care partners' revenue and 40% of owned membership are now in full-risk arrangements.
Expansion in Southern Nevada and Texas: Southern Nevada reached run-rate profitability in 2025 and continues to perform well. In Texas, the launch of a full-risk delegated model with a large payer partner is progressing as expected.
Revenue growth: Revenue for Q1 2026 was $965.1 million, up 56% year-over-year, driven by new full-risk contracts, Prospect contribution, and organic growth.
AI operational efficiencies: AI agents reduced provider payment cycle times by over 50% and improved clinical outcomes, such as a 24% higher gap closure rate and a 30% higher annual wellness visit completion rate.
Cost management: Medical cost trends slightly outperformed the full-year assumption of 5.2%, with strong performance across core and legacy populations.
Prospect integration: Integration of Prospect is on track, with financial standardization completed and clinical workflows aligned. Gross provider retention remains above 99%, and the company is tracking towards the high end of its $12-$15 million annual synergy target.
Deleveraging: Net leverage declined to 2.3x on a pro forma basis, ahead of schedule, with expectations to end the year at or below 2 turns of net leverage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicaid and Exchange Membership Trends: Attrition in Medicaid membership tracked modestly below expectations, while exchange attrition was ahead of expectations. These dynamics could impact revenue and patient engagement.
Regulatory Changes: Changes in Medicare Advantage risk adjustment frameworks could impact industry performance. However, Astrana's conservative approach positions it relatively well.
Integration of Prospect: While integration is on track, achieving the high end of the $12 million to $15 million synergy target remains a challenge.
Full Risk Contracts: New full-risk contracts are performing in line with expectations, but their success depends on disciplined execution and risk management.
Economic and Market Conditions: The company assumes conservative Medicaid membership trends and adverse selection, which could affect financial performance if conditions worsen.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Astrana Health reaffirms its full-year 2026 revenue guidance in the range of $3.8 billion to $4.1 billion. For the second quarter of 2026, revenue is expected to be between $965 million and $1 billion.
Adjusted EBITDA Guidance: The company expects full-year 2026 adjusted EBITDA to be between $250 million and $280 million. For the second quarter of 2026, adjusted EBITDA is projected to range from $65 million to $70 million.
Free Cash Flow Guidance: Astrana Health anticipates full-year 2026 free cash flow to be between $105 million and $132.5 million, supported by new full-risk contracts, normalized working capital, and reduced integration-related investments.
Medical Cost Trend: The company assumes a blended medical cost trend of approximately 5.2% for 2026, with Q1 actuals performing at or better than planned levels.
Membership Trends: Medicaid membership attrition is tracking modestly below expectations, while exchange attrition is slightly ahead of expectations. Overall, the company maintains a conservative outlook for 2026 membership trends.
Deleveraging Goals: Astrana Health aims to end 2026 with net leverage at or below 2 turns, supported by profitable growth, free cash flow generation, and disciplined debt reduction.
Prospect Integration: The integration of Prospect is on track, with financial standardization completed and clinical workflows aligned. The company expects to achieve the high end of its $12 million to $15 million annual synergy target.
Expansion Markets: In Southern Nevada, the company expects continued strong performance following a 20% year-over-year improvement in MLR. In Texas, the full-risk delegated model launched in January 2026 is progressing as planned, with expectations for a similar maturation curve as other markets.
Regulatory Environment: Astrana Health is well-positioned under the revised 2027 Medicare Advantage framework due to its conservative approach to risk adjustment and focus on clinical execution and cost management.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on enrollment and trend in Medicare Advantage, Medicaid, and exchange programs?
A:Medicare enrollment showed mid-single-digit growth in eligibility. Medicaid disenrollment tracked slightly ahead of the midpoint of the range, likely ending at the high end for the year. Exchange disenrollments were better than expected. Overall, trend performed well across all lines of business, with a blended 5.2% cost trend year-over-year. Medicaid trend was better than expected due to lower adverse selection.
Q:What are your thoughts on capital allocation and the best use of cash?
A:The focus remains on deleveraging following the Prospect transaction, with net leverage already declining to approximately 2.3 turns on a pro forma TTM basis. Capital deployment priorities include investing in technology infrastructure, AI capabilities, clinical operations, and expansion markets. M&A will be approached selectively, focusing on capital-efficient ways to expand membership and market density. Share repurchases will be evaluated dynamically based on risk-adjusted returns.
Q:How much more leverage does the Astrana operating platform have to drive G&A efficiencies, and what new programs are being launched?
A:The platform has opportunities to expand agentic care management workflows and integrate Prospect onto the Astrana operating system, which can drive further operating leverage and medical cost leverage. G&A as a percentage of revenue has already reduced by 70 basis points year-over-year, with expectations to exit the year even lower. The Care Enablement segment continues to grow rapidly, adding new clients and offering tools to improve care management.
Q:What is the status of the quality assurance fund and its potential contribution to this fiscal year?
A:The quality assurance fund update is expected in the third or fourth quarters. Out of conservatism, its contribution has been excluded from the 2026 guidance.
Q:Are you feeling better about the 2027 EBITDA target of $350 million given recent developments?
A:The company remains cautiously optimistic about the 2027 EBITDA target. Despite a different regulatory environment, the Astrana platform has shown consistent performance, with a 32% revenue CAGR and 25% adjusted EBITDA CAGR from 2019 through 2026 guidance. The business is positioned to grow organically at a mid to high teens rate, with potential acceleration through selective M&A.
Q:How are AI investments split between administrative and clinical aspects, and what benefits have been observed?
A:AI investments have been infused across the board, with a meaningful part of the 70 basis point G&A improvement attributed to AI. Initially focused on administrative functions like claims and authorizations, investments have expanded to clinical tools like risk stratification and care management. These tools are expected to improve medical loss ratios (MLR) over time, as seen with Prospect's performance improvements.
Q:What are your thoughts on the future of risk adjustment models in Medicare Advantage?
A:The company supports the idea of AI-inferred risk scores to determine a member's true acuity, which could standardize risk determination and reduce reliance on documentation optimization. Astrana's conservative approach to risk adjustment positions it well for such changes, potentially benefiting from a more accurate determination of patient risk.
Q:What structural differences give Astrana an advantage in leveraging AI compared to peers?
A:Astrana's AI-native tech platform and integrated data infrastructure provide a strong foundation for embedding AI across workflows. In contrast, peers with legacy systems and fragmented data may struggle to build effective AI solutions. Astrana's approach allows for rapid adoption and integration of AI into operational, clinical, and quality of care workflows.
Q:What is the impact of the final Medicare Advantage rate notice on Astrana?
A:The final rate notice is constructive, with an effective growth rate of 5.33%. For Astrana, the average change is approximately 4%, which aligns with its current RAF levels and supports maintaining MA margins consistent with 2026. Additional tailwinds from risk adjustment improvements are possible.
Q:What are the margins for fully capitated books of business, and how are they distributed geographically?
A:Fully capitated arrangements start with lower EBITDA margins but mature over time to align with partial risk members. Most full risk members are in California, with additional members in Texas and Nevada. The ACO REACH business also includes full risk arrangements. Most full risk contracts exclude Part D risk.
Q:What are the potential revenue synergies from the Prospect acquisition?
A:Revenue synergies have not been quantified but are expected over time as the denser network improves access to high-quality care. The $12 million to $15 million synergy range does not include revenue synergies.
Q:How is the transition to full risk contracts progressing?
A:Approximately 40% of members are now in full risk arrangements, translating to 80% of care partners' revenue. The transition is ahead of schedule, with continued growth in full risk members expected over time.
Q:How is Astrana expanding its delegated model into new markets?
A:Astrana uses a stepwise approach, starting with partial risk arrangements to establish data feeds, provider relationships, and care management systems. This approach allows for gradual adoption of the delegated model in new states and geographies, such as Texas and Nevada.
Q:How have longitudinal patient relationships impacted Medicaid acuity?
A:Astrana's longitudinal care model, which allows members to maintain the same care team across different insurance lines, has mitigated adverse selection in Medicaid. Members engaged in this model tend to have higher acuity and utilization, reducing the impact of disenrollment.
Q:What is the updated expectation for ACA attrition, and when will membership guidance be revised?
A:Initial guidance projected 30%-40% ACA disenrollment, but current trends suggest 20%-30%. Membership guidance may be revised later in the year as more data becomes available.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the quality assurance fund's timing and potential contribution, stating only that updates are expected in the third or fourth quarters. Additionally, revenue synergies from the Prospect acquisition were not quantified, and management did not provide specific details on the impact of AI investments on G&A improvements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI advantage
AI agent
AI model
AI patient
AI platform
AI relationship
AI task
AI value
Astrana Non
Astrana start
Astrana system
Care model
Exchange trend
MLR Texas
MSSP scalability
Medicaid membership
Medicare population
Sim
accountability system
action
advantage Astrana
attrition
capability
consistency
continuity
contract line
discipline
expansion market
intelligence
journey
line underwriting
orchestration
outreach
pillar
resource
result advantage
risk progression
setting
source
turn leverage
workflow care
ASTH Transcript
Astrana Health, Inc. (ASTH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Astrana Health, Inc. (ASTH) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights strong revenue and EBITDA growth projections, a positive impact from Medicare Advantage rate adjustments, and successful AI integration. The Q&A session reinforces these positives with details on AI benefits and strategic advantages. Despite some uncertainties, the overall sentiment is optimistic, suggesting a positive stock price movement.
Astrana Health, Inc. (ASTH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Astrana Health, Inc. (ASTH) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call indicates strong financial performance with record-high adjusted EPS and optimistic guidance for 2026 and 2027. The integration of Prospect Health and strategic partnerships are progressing well, and AI tools are enhancing operational efficiency. Despite some concerns about Medicaid disenrollments and management's lack of specific quantifications, the overall sentiment is positive. The expanded partnerships and AI deployment are likely to boost short-term stock price, leading to a positive outlook.
ASTH Slides
Astrana Health Q1 2026 slides: 56% revenue growth, full-risk shift accelerates2026-05-07
Astrana Health Q3 2025 slides: Revenue doubles while EPS disappoints2025-11-06
Astrana Health Q2 2025 slides: Revenue surges 35% amid declining margins2025-08-07
Astrana Health Q1 2025 slides: 53% revenue growth amid profitability challenges2025-05-08
ASTH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
